Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals — Investor Presentation (August 2024)

32 slides from Longboard Pharmaceuticals's investor presentation, Aug 1, 2024

  1. Slide 1: Corporate Presentation

    Exhibit 99.2 Corporate Presentation AUGUST 1, 2024 1 LONGBOARD PHARMACEUTICALS

  2. Slide 2: Forward-Looking Statements and Other Legal Notices

    Forward-Looking Statements and Other Legal Notices This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our vision; commercial opportunities and analogs; the potential of bexicaserin (LP352)

  3. Slide 3: Our Vision is Backed by 20+ Years of World Class GPCR Research

    Differentiated & innovative clinical approaches CNS programs with significant Bold & experienced commercial opportunities leadership with LONGBOARD THESIS expertise in CNS and rare disorders Our Vision is Backed by 20+ Years of World Class GPCR Research VISION A world where devastating neurological

  4. Slide 4: Longboard's Potentially Best-in-Class Product Candidates

    Longboard’s Potentially Best-in-Class Product Candidates Program MOA Therapeutic Preclinical Ph I Ph II Ph III Milestones Area PACIFIC Study Topline Data – Q1 2024 PACIFIC OLE Data – Q2 2024 DEEs and other End of Phase 2 Meeting – Q2 Bexicaserin 5-HT2C refractory 2024 (LP352) Superagonist epilepsies

  5. Slide 5: Developmental & Epileptic Encephalopathies (DEE) Landscape

    Developmental & Epileptic Encephalopathies (DEE) Landscape 5 LONGBOARD PHARMACEUTICALS

  6. Slide 6: 4 DEE Syndromes Have Approved Therapies; 20+ Have None

    4 DEE Syndromes Have Approved Therapies; 20+ Have None “Approved 4” DEE Prevalence (US) Other DEEs ~48,000 ~50,000 • DUP15q Syndrome • Rett Syndrome • SCN2A-DEE • Ohtahara Syndrome • SCN8A-DEE • PCDH19 • KCNQ2-DEE • EE w/ Continuous • KCNQ3-DEE Spike-Wave ~21,000 • Angelman Syndrome • Myoclonic Aton

  7. Slide 7: Nearly All Surveyed HCPs Treat Patients with All DEE Diagnoses

    Nearly All Surveyed HCPs Treat Patients with All DEE Diagnoses; Collectively, the Number of “Other DEEs” is Significant DEE Types Treated in the Past 12 Months Percent of Patients with DEE Type 92% 94% 50% 79% 79% 48% 27% 11% 8% 4% Dravet LGS TSC CDD Other DEEs Dravet LGS TSC CDD Other DEEs 7 LONGBO

  8. Slide 8: Bexicaserin (LP352)

    Bexicaserin (LP352) Potential Best-in-Class 5-HT2C Superagonist - Entering a Ph 3 Program with the Goal of Treating a Broad Range of DEEs 8 LONGBOARD PHARMACEUTICALS

  9. Slide 9: The Potential of Bexicaserin

    9 The Potential of Bexicaserin Greater Selectivity and Specificity Clinical Validation in DEE Participants • Designed to bind only to the 5-HT2C receptor • No detected activity at receptors associated with significant AEs: 5-HT2B (VHD and PAH) & 5-HT2A (psychiatric)* Improvement in Median Countable

  10. Slide 10: Bexicaserin Designed to be a Next-Generation 5-HT2C with Greater Selectivity and Specificity

    Bexicaserin (LP352) Designed to be a Next-Generation 5-HT2C with Greater Selectivity and Specificity 5-HT2A 5-HT2B Serotonin Potential Adverse Receptor Events Subtype Per Receptor Subtype EC50, nM Ki, nM 5-HT2C ~120 ~50 CNS, GI Bexicaserin (LP352) 5-HT2C 5-HT2B Not detectable Not detectable n/a Supe

  11. Slide 11: Surveyed HCPs Evaluate ASMs by Balancing Efficacy, Safety & Burden

    Surveyed HCPs Evaluate ASMs by Balancing Efficacy, Safety & Burden Influence on ASM Decisions Unmet Need for New ASM Approved to Treat a When allocating 100 points across factors Broad Range of DEE Types 34% Efficacy 83% 57% 7- Significant unmet need Believe there 21% Safety is a significant Safety

  12. Slide 12: Bexicaserin Ph 1b/2a PACIFIC Study in Participants with DEEs

    Bexicaserin (LP352) Ph 1b/2a PACIFIC Study in Participants with DEEs Treatment Period Screening Randomization & Maintenance* Down- Follow-up Period Up-Titration Titration Period 5 Wks Days 1-15 Days 16-75 Days 76- 30 Days 80/90** LP352 (n=43) 6 mg 9 mg 12 mg Participant remains on 6, 9 or Open- 12 m

  13. Slide 13: Participant Disposition and Safety

    Participant Disposition and Safety Overall (N = 52) Bexicaserin Placebo (N=43) (N=9) Bexicaserin Placebo n (%) n (%) Parameter n (%) (n=43) (n=9) Safety Set 43 (100) 9 (100) Somnolence 12 (27.9) 1 (11.1) Full Analysis Set 35 (81.4) 9 (100) Decreased Participants Completed 32 (74.4) 9 (100) Most Comm

  14. Slide 14: Bexicaserin Achieved Median Observed Countable Motor Seizure Reduction of 59.8%

    Bexicaserin Achieved Median Observed Countable Motor Seizure Reduction of 59.8% vs. 17.4% Placebo Across the DEE Study Population 0% Median Percent Change from -10% -17.4% -20% Baseline -30% -40% -59.8% -50% -60% Bexicaserin -70% Δ 42.4% (p-value = 0.0538) Placebo Bexicaserin Achieved Placebo Adjust

  15. Slide 15: Median Seizure Reduction Across Dravet, LGS, DEE Other Cohorts

    Bexicaserin (LP352) Achieved Median Seizure* Reduction Across Dravet, LGS, DEE Other Cohorts Δ 33.4% Δ 33.3% 0% -10% -17.4% n=5 Median Percent Change from Baseline -20% Placebo -30% -32.2% n=4 Placebo -40% -50% -50.8% n = 17 Bexicaserin -60% -65.5% n = 15 -70% -74.6% Bexicaserin n=3 -80% Bexicaserin

  16. Slide 16: Individual Percent Change from Baseline in Observable CMS Frequency

    Individual Percent Change from Baseline in Observable CMS Frequency During Treatment Period and Encephalopathy Type Bexicaserin Bexicaserin Placebo Bexicaserin Placebo 175 150 Individual Percent Change from Baseline 125 100 75 50 25 0 -25 -50 -75 -100 Dravet LGS DEE Other 16 LONGBOARD PHARMACEUTICAL

  17. Slide 17: Summary: Interim Analysis from Bexicaserin OLE Study

    Summary: Interim Analysis from Bexicaserin (LP352) OLE Study • 100% of PACIFIC completers continued into Median Observed Countable Motor Seizure Reduction Across OLE (95.1% in OLE at 6-months) DEE Study Population* • PACIFIC completers n=41(DS=3, LGS=20, DEE Other=18) 0% Bexicaserin 201 / Placebo 20

  18. Slide 18: Bexicaserin Median Observed Countable Motor Seizure Reduction in OLE

    Bexicaserin (LP352) Median Observed Countable Motor Seizure Reduction in OLE Open-Label Extension* (6-Month Treatment Period) 20 Median Percent Seizure Reduction 0 from PACIFIC Baseline -20 -40 50% Reduction -60 Bexicaserin 201 / Transition to Bexicaserin OLE OLE dose -80 Placebo 201 / Bexicaserin O

  19. Slide 19: Bexicaserin Phase 3 Global Program – DEE Path Forward

    Bexicaserin Phase 3 Global Program – DEE Path Forward Subject to Ongoing Discussions with Regulatory Agencies Study 301: DEEs (LGS + Other DEEs) Expected to be run in parallel Study 302: Dravet Syndrome Planned Study Parameters: Primary Endpoint: Reduction in Countable Motor Seizures Ages: ≥ 2 to ≤

  20. Slide 20: Global Phase 3 Program Expected to Initiate in 2024

    20 Global Phase 3 Program Expected to Initiate in 2024 Bexicaserin (LP352) achieved a median percent reduction from baseline in seizure frequency during the treatment period of: 59.8% in broad DEE population (42.4% placebo-adjusted) 74.6% in Dravet cohort 50.8% in LGS cohort (33.4% placebo-adjusted)

  21. Slide 21: LP659

    LP659 Centrally Acting, Highly Selective Sphingosine-1-Phosphate (S1P) Receptor Modulator Targeting Multiple Neurological Diseases 21 CONFIDENTIAL | LONGBOARD PHARM ACEUTICALS

  22. Slide 22: S1PR1 Modulation Selectively Reduces Migration of Lymphocytes From Lymph Nodes

    S1PR1 Modulation Selectively Reduces Migration of Lymphocytes From Lymph Nodes Treatment with S1P Receptor Modulator • Functionally antagonizes S1PR1 by inducing receptor internalization and degradation, disrupting normal lymphocyte subset egress • Decreases release of inflammatory cytokines and red

  23. Slide 23: LP659 Selectivity & Potential in Neurodegenerative Disease Therapy

    LP659 Selectivity & Potential in Neurodegenerative Disease Therapy LP659 No Activity LP659 S1P1 S1P5 S1P4 S1P2 S1P3 β-Arrestin EC50 0.64 nM 12.2 nM 121 nM NR NR Emax 116% 66% 32% Astrocyte Neuron Oligodendrocyte Microglia T-Lymphocytes Reduces Immune Cell Migration, Differentiation & Believed not to

  24. Slide 24: LP659 Designed to be a Next Generation Centrally-Acting S1PR1 Agonist

    LP659 Designed to be a Next Generation Centrally-Acting S1PR1 Agonist with Greater Selectivity and Internalization- Biased Signaling Most potent at S1PR1 Greatest selectivity towards LP659 S1PR1 over S1PR5 internalization 25 50 Fold-selectivity S1PR1/5 S1PR1 Relative Potency S1PR1 20 40 30 15 20 10

  25. Slide 25: LP659 Reduced Circulating T and B Cells While Maintaining Immunosurveillance

    LP659 Reduced Circulating T and B Cells While Maintaining Immunosurveillance • LP659 potency in vivo parallels T and B cell lowering potential • Proportion of Tregs over total CD4+ cells is significantly increased by LP659 • No significant effects on NK and monocyte frequencies T Cells B Cells Treg/

  26. Slide 26: LP659 Phase 1 SAD Topline Data

    LP659 LP659 Phase 1 SAD Topline Data 26 CONFIDENTIAL | LONGBOARD PHARM ACEUTICALS

  27. Slide 27: LP659-101: A Phase 1 SAD Study in Adult Healthy Volunteers

    LP659-101: A Phase 1 SAD Study in Adult Healthy Volunteers A Phase 1, First-In-Human, Randomized, Double Blind, Placebo Controlled, Single 28 Days Day 1 Day 8 Day 15 Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics and SAD Cohorts 1, 2 and 4 (n=8) Pharmacodynamics of LP659 I

  28. Slide 28: Phase 1 Safety Results

    Phase 1 Safety Results Adverse events were mild No TEAEs leading to discontinuation LP659 was generally safe and well tolerated ► No SAEs observed Impact on HR was low throughout the study with no first dose bradycardia No abnormal ECGs (no AV block) or abnormal echocardiograms No abnormal pulmonary

  29. Slide 29: Mean Percent Change from Baseline in Absolute Lymphocyte Count 1–24 Hours Post-Dose

    Mean Percent Change from Baseline in Absolute Lymphocyte Count 1–24 Hours Post-Dose The mean percent change from baseline in ALC at Hour 6 post-dose: LP659 Dose A (Formulation 1) -3.5% LP659 Dose B (Formulation 1) -0.9% LP659 Dose C (Formulation 1) -18.8% LP659 Dose C (Formulation 2) -58.9% LP659 Do

  30. Slide 30: New Opportunities in Immune & Inflammatory Conditions

    New Opportunities in Immune & Inflammatory Conditions RATIONALE FOR S1P1/5 RECEPTOR MODULATOR USE Autoimmune • S1PR1 is a clinically validated target for treating Chronic multiple autoimmune conditions including MS & IBD Guillain-Barré Inflammatory Autoimmune • T cell-mediated autoimmunity is known

  31. Slide 31: Financial Summary & Milestones

    Financial Summary & Milestones Cash, Cash Equivalents Key Milestones Anticipated Timing & Investments PACIFIC Ph 1b/2a Topline Data Q1 2024 $304.9 million As of June 30, 2024 PACIFIC Open-Label Extension Data Q2 2024 Bexicaserin Shares Outstanding End of Phase 2 Meeting Q2 2024 (LP352) 38.9 million

  32. Slide 32: Thank you

    Thank you Nasdaq: LBPH IR@LONGBOARDPHARMA.COM 32 LONGBOARD PHARMACEUTICALS

Longboard Pharmaceuticals — Investor Presentation (August 2024) on 6ix